Lysosomal Storage Disorders
This book is dedicated to patients affected by Lysosomal Storage Disorders, and especially to the National Gaucher Foundation (USA) and the Colombian Association of Patients with Lysosomal Storage Diseases (ACOPEL for its Spanish Acronym). Both organizations will share in the sales of this book.
Allosteric Regulatory Enzymes
This book provides a logical introduction to the limits for enzyme function as dictated by the factors that are limits for life. This book presents a complete description of all the mechanisms used for changing enzyme acticity. Eight enzymes are used as model systems after extensive study of their mechanisms. Wherever possible, the human form of the enzyme is used to illustrate the regulatory features.
Bioactive Heterocycles III
Bioactive Heterocycles III provides readers with a comprehensive overview of the most recent breakthroughs in the ?eld of heterocycles. This volume contains 8 chapters written by experts in their respective ?elds from all over the world. The chapters summarize years of extensive research in each area, and providein sight in the new themesofnaturalproduct research.Manyofthe contributors illustrate their laboratory experiences. It's obvious that readers will gain exciting and essential information fromthe volume. In the ?rst chapter, Kayser et al. describe the chemistry, biosynthesis and biological activities of artemisinin, one of the most promising antimalarial molecules, and its related natural peroxides.
Alzheimers Disease
Alzheimer’s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasing socioeconomic threat in the future. Current medicines for AD patients are mainly symptomatic treatments and a huge unmet medical need exists to slow the progression of this disease. A great deal of research has been dedicated to understanding the pathogenesis of AD from which comes many ideas for intervening with its progression. Some of these ideas have been fast-tracked to clinical trials due to the availability of medicines with proven clinical efficacies for other diseases (e.g. atorvastatin, simvastatin, rosiglitazone and clioquinol) while others represent novel chemical entities (e.g. glycogen synthase kinase-3 inhibitors).



